SG11201505520WA - 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS - Google Patents
2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORSInfo
- Publication number
- SG11201505520WA SG11201505520WA SG11201505520WA SG11201505520WA SG11201505520WA SG 11201505520W A SG11201505520W A SG 11201505520WA SG 11201505520W A SG11201505520W A SG 11201505520WA SG 11201505520W A SG11201505520W A SG 11201505520WA SG 11201505520W A SG11201505520W A SG 11201505520WA
- Authority
- SG
- Singapore
- Prior art keywords
- dihydroimidazol
- pyrimidin
- pla
- inhibitors
- associated phospholipase
- Prior art date
Links
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 title 1
- YHPVIBUEXBEHPV-UHFFFAOYSA-N 2,6-dihydro-1h-pyrimidin-5-one Chemical compound O=C1CNCN=C1 YHPVIBUEXBEHPV-UHFFFAOYSA-N 0.000 title 1
- 108010024976 Asparaginase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013070976 | 2013-01-25 | ||
| CN2013001556 | 2013-12-12 | ||
| PCT/EP2014/051286 WO2014114694A1 (en) | 2013-01-25 | 2014-01-23 | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505520WA true SG11201505520WA (en) | 2015-08-28 |
Family
ID=50002724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505520WA SG11201505520WA (en) | 2013-01-25 | 2014-01-23 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS |
Country Status (23)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6306053B2 (ja) | 2013-01-25 | 2018-04-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | ２，３−ジヒドロイミダゾール［１，２−ｃ］ピリミジン−５（１Ｈ）−オンに基づくリポタンパク質関連ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）阻害剤 |
| WO2016012917A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| AU2015292048B2 (en) | 2014-07-22 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| CN104892459A (zh) * | 2015-06-16 | 2015-09-09 | 苏州明锐医药科技有限公司 | 利奥西呱中间体及其制备方法 |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| WO2021089032A1 (zh) * | 2019-11-09 | 2021-05-14 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN111533699B (zh) * | 2020-05-27 | 2023-12-01 | 龙曦宁（上海）医药科技有限公司 | 一种2-（三氟甲基）嘧啶-5-醇的合成方法 |
| CN113861220B (zh) * | 2020-06-30 | 2023-06-16 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113912622B (zh) * | 2020-07-10 | 2023-12-01 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN114057740B (zh) * | 2021-12-15 | 2024-04-02 | 上海赛默罗生物科技有限公司 | 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN116120329B (zh) * | 2022-08-04 | 2025-05-09 | 福贝生物医药科技(北京)有限公司 | 作为Lp-PLA2抑制剂的化合物及其用途 |
| CN116925023A (zh) * | 2023-07-18 | 2023-10-24 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| SK80397A3 (en) | 1994-12-22 | 1998-01-14 | Smithkline Beecham Plc | Substituted azetidin-2-ones, preparation method thereof, farmaceutical compositions and their use |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| EA199800109A1 (ru) | 1995-07-01 | 1998-10-29 | Смитклайн Бичам Плс | Производные азетидинона для лечения атеросклероза |
| CA2233300A1 (en) | 1995-09-29 | 1997-04-10 | Christopher Donald Southan | A paf-acetylhydrolase and use in therapy |
| JP2000502079A (ja) | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体 |
| WO1997021676A1 (en) | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| HUP9901359A3 (en) | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| EP1028955B1 (en) | 1997-11-06 | 2003-07-16 | SmithKline Beecham plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
| WO2000010980A1 (en) | 1998-08-21 | 2000-03-02 | Smithkline Beecham Plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| MXPA01011186A (es) | 1999-05-01 | 2002-08-12 | Smithkline Beecham Plc | Compuestos de pirimidinona. |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| JP3757703B2 (ja) | 1999-09-22 | 2006-03-22 | 凸版印刷株式会社 | 再封可能な開口維持部材付パウチ |
| DK1263740T3 (da) | 2000-02-16 | 2006-11-13 | Smithkline Beecham Plc | Pyrimidin-4-on-derivat som LDL-PLA2-inhibitor |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| GB0119793D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127143D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
| GB0127140D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| CA2530816A1 (en) | 2003-07-02 | 2005-01-13 | Bayer Healthcare Ag | Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases |
| DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
| US20080090851A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US20080090852A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| WO2008048867A2 (en) | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| WO2008141176A1 (en) | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| US8871928B2 (en) * | 2010-09-20 | 2014-10-28 | Glaxo Group Limited | Tricyclic compounds, preparation methods, and their uses |
| JP2013544854A (ja) * | 2010-12-06 | 2013-12-19 | グラクソ グループ リミテッド | 化合物 |
| JP2013545792A (ja) | 2010-12-17 | 2013-12-26 | グラクソ グループ リミテッド | 眼疾患の処置および防止方法 |
| CN103827116B (zh) * | 2011-07-27 | 2016-08-31 | 葛兰素集团有限公司 | 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物 |
| KR20140059203A (ko) * | 2011-07-27 | 2014-05-15 | 글락소 그룹 리미티드 | 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도 |
| JP6306053B2 (ja) | 2013-01-25 | 2018-04-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | ２，３−ジヒドロイミダゾール［１，２−ｃ］ピリミジン−５（１Ｈ）−オンに基づくリポタンパク質関連ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）阻害剤 |
-
2014
- 2014-01-23 JP JP2015554138A patent/JP6306053B2/ja not_active Expired - Fee Related
- 2014-01-23 EP EP14701355.1A patent/EP2948452B1/en active Active
- 2014-01-23 TW TW103102388A patent/TW201443054A/zh unknown
- 2014-01-23 WO PCT/EP2014/051286 patent/WO2014114694A1/en active Application Filing
- 2014-01-23 CN CN201480013675.8A patent/CN105008368B/zh not_active Expired - Fee Related
- 2014-01-23 EA EA201591379A patent/EA025885B1/ru not_active IP Right Cessation
- 2014-01-23 ES ES14701355.1T patent/ES2642762T3/es active Active
- 2014-01-23 CA CA2899091A patent/CA2899091A1/en not_active Abandoned
- 2014-01-23 HK HK16104389.3A patent/HK1216425A1/zh unknown
- 2014-01-23 PE PE2015001537A patent/PE20151251A1/es not_active Application Discontinuation
- 2014-01-23 MX MX2015009633A patent/MX2015009633A/es unknown
- 2014-01-23 BR BR112015017759-0A patent/BR112015017759B1/pt not_active IP Right Cessation
- 2014-01-23 AU AU2014209949A patent/AU2014209949B2/en not_active Ceased
- 2014-01-23 SG SG11201505520WA patent/SG11201505520WA/en unknown
- 2014-01-23 MA MA38284A patent/MA38284B1/fr unknown
- 2014-01-23 KR KR1020157022396A patent/KR20150108897A/ko not_active Ceased
- 2014-01-23 UY UY0001035276A patent/UY35276A/es not_active Application Discontinuation
- 2014-01-23 US US14/761,636 patent/US9708330B2/en not_active Expired - Fee Related
-
2015
- 2015-07-13 ZA ZA2015/05025A patent/ZA201505025B/en unknown
- 2015-07-20 IL IL240046A patent/IL240046A0/en unknown
- 2015-07-20 PH PH12015501586A patent/PH12015501586A1/en unknown
- 2015-07-23 CL CL2015002060A patent/CL2015002060A1/es unknown
- 2015-07-24 CR CR20150390A patent/CR20150390A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9708330B2 (en) | 2017-07-18 |
| MA38284A1 (fr) | 2017-12-29 |
| CR20150390A (es) | 2015-10-19 |
| BR112015017759B1 (pt) | 2022-05-24 |
| JP6306053B2 (ja) | 2018-04-04 |
| JP2016505058A (ja) | 2016-02-18 |
| PH12015501586A1 (en) | 2015-10-05 |
| UY35276A (es) | 2014-08-29 |
| EP2948452B1 (en) | 2017-08-09 |
| ZA201505025B (en) | 2017-08-30 |
| US20150361082A1 (en) | 2015-12-17 |
| TW201443054A (zh) | 2014-11-16 |
| MA38284B1 (fr) | 2018-05-31 |
| EA025885B1 (ru) | 2017-02-28 |
| CN105008368A (zh) | 2015-10-28 |
| EA201591379A1 (ru) | 2016-01-29 |
| BR112015017759A2 (pt) | 2017-07-11 |
| CA2899091A1 (en) | 2014-07-31 |
| KR20150108897A (ko) | 2015-09-30 |
| AU2014209949B2 (en) | 2016-09-08 |
| HK1216425A1 (zh) | 2016-11-11 |
| PE20151251A1 (es) | 2015-09-10 |
| CL2015002060A1 (es) | 2015-11-27 |
| AU2014209949A1 (en) | 2015-07-30 |
| IL240046A0 (en) | 2015-08-31 |
| EP2948452A1 (en) | 2015-12-02 |
| CN105008368B (zh) | 2017-02-01 |
| MX2015009633A (es) | 2015-11-30 |
| ES2642762T3 (es) | 2017-11-20 |
| WO2014114694A1 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201505520WA (en) | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS | |
| IL265253A (en) | Reversible pyrimidine compounds inhibit bmi–1 | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| PL3379933T3 (pl) | KOMPOZYCJE GRZYBOBÓJCZE ZAWIERAJĄCE POCHODNE 2,4-DIOKSO-1,4-DIHYDROTIENO[2,3-d]PIRYMIDYNY | |
| EP3039015A4 (en) | Substituted pyrimidine bmi-1 inhibitors | |
| ZA201505454B (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) | |
| ZA201307839B (en) | Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors | |
| IL236004A0 (en) | Solid states of an antiviral compound | |
| EP3016953A4 (en) | Purinone compounds as kinase inhibitors | |
| IL243092A0 (en) | New triazolo[d–4,5]pyrimidine histories | |
| EP3067356A4 (en) | Pyrrolo pyrimidine derivative | |
| AP3751A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| SI2935274T1 (sl) | 3-okso-2,3,5,8-tetrahidro-(1,2,4)triazolo(4,3-a)pirimidinski derivati za zdravljenje bolezni dihal | |
| EP2739627A4 (en) | 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2 | |
| ZA201406038B (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| ZA201403441B (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid | |
| PT2694513E (pt) | Derivados de pirazolopirimidina | |
| IL244817A0 (en) | Transmuted pyrimidine compounds and their use as syk inhibitors | |
| EP3294297A4 (en) | Pyrimidinone amide compounds as pde2 inhibitors | |
| PL2948443T3 (pl) | Nowe pochodne pirymidyny jako inhibitory fosfodiesterazy 10 (pde-10) | |
| HK1224675A1 (en) | Purinone compounds as kinase inhibitors |